Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations

Arvinas Inc ARVN announced interim data from its Phase 1/2 dose escalation and expansion trial of ARV-766 in metastatic castration-resistant prostate cancer. 

Data from the Phase 1/2 dose escalation and expansion trial show that ARV-766 was well-tolerated and demonstrated promising activity in a heavily pre-treated, post-NHA, all-comers patient population.

Across the Phase 1 and interim Phase 2 data, ARV-766 achieved a 42% PSA50 (reduction of 50% in prostate-specific antigen) in patients with AR LBD mutations. 

Three of 5 patients with AR L702H mutations achieved PSA50; the three responding AR L702H patients had co-occur T878/H875 mutations.

Two of 4 RECIST-evaluable patients with tumors harboring AR LBD mutations had a best-observed response of partial response (1 confirmed partial response, one unconfirmed partial response).

ARV-766 has been well tolerated, and most treatment-related adverse events (TRAEs) have been Grade 1 or 2, with no Grade ≥4 TRAEs and no dose-limiting toxicities.

Price Action: ARVN shares are down 2.83% at $23.33 during the session on the last check Thursday.